CA Patent

CA3221851A1 — Positron emitting radionuclide labeled peptides for human upar pet imaging

Assigned to Curasight AS · Expires 2014-06-12 · 12y expired

What this patent protects

A positron-emitting radionuclide labelled peptide conjugate for use in the prediction/diagnosis of aggressiveness, prognosis, progression or recurrence by PET imaging of urokinase-type plasminogen activator receptor (uPAR) expressing tumors in a human is disclosed. The conjugate …

USPTO Abstract

A positron-emitting radionuclide labelled peptide conjugate for use in the prediction/diagnosis of aggressiveness, prognosis, progression or recurrence by PET imaging of urokinase-type plasminogen activator receptor (uPAR) expressing tumors in a human is disclosed. The conjugate comprises a uPAR binding peptide coupled via the chelating agent DOTA or NOTA to a 68Ga radionuclide.

Drugs covered by this patent

Patent Metadata

Patent number: CA3221851A1
Jurisdiction: CA
Classification: —
Expires: 2014-06-12
Drug substance claim: No
Drug product claim: No
Assignee: Curasight AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.